Cargando…

P1237: PRELIMINARY RESULTS OF A PHASE Ⅱ STUDY OF ZANUBRUTINIB COMBINED WITH IMMUNOCHEMOTHERAPY IN PATIENTS WITH CD79A/CD79B-MUTANT DIFFUSE LARGE B-CELL LYMPHOMA

Detalles Bibliográficos
Autores principales:	Yan, Z., Yao, S., Wang, H., Chu, J., Zhao, S., Ma, J., Wei, B., Zheng, J., Lin, Q., Xu, Z., yao, Z., liu, Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430540/ http://dx.doi.org/10.1097/01.HS9.0000847812.32219.ad

Ejemplares similares

United we stand: Double targeting of CD79B and CD20 in diffuse large B‐cell lymphoma
por: Tarantelli, Chiara, et al.
Publicado: (2022)

Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma
por: Nagel, Daniel, et al.
Publicado: (2015)

Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
por: Chu, Fuliang, et al.
Publicado: (2023)

Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells
por: He, Xiaocui, et al.
Publicado: (2018)

Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations
por: Kersten, M J, et al.
Publicado: (2014)

CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma
por: Trøen, Gunhild, et al.
Publicado: (2013)

Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice
por: Visco, Carlo, et al.
Publicado: (2020)

Spatial transcriptome of a germinal center plasmablastic burst hints at MYD88/CD79B mutants‐enriched diffuse large B‐cell lymphomas
por: L'Imperio, Vincenzo, et al.
Publicado: (2022)

PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS
por: Zhou, Jihao, et al.
Publicado: (2022)

High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites
por: Kraan, W, et al.
Publicado: (2013)

Human CD79b(+) neutrophils in the blood are associated with early-stage melanoma
por: Meyer, Melissa A., et al.
Publicado: (2023)

Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma
por: Sakatani, Akio, et al.
Publicado: (2020)

Possible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia
por: Jovanovic, Danijela, et al.
Publicado: (2014)

Anti‐CD22 and anti‐CD79b antibody‐drug conjugates preferentially target proliferating B cells
por: Fuh, Franklin K, et al.
Publicado: (2017)

Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas
por: Yi, Jun Ho
Publicado: (2021)

Prevalence And Clinical Significance Of Oncogenic CD79B And MYD88 Mutations In Primary Testicular Diffuse Large B-Cell Lymphoma: A Retrospective Study In China
por: Chen, Yan-ping, et al.
Publicado: (2019)

Occurrence of MYD88L265P and CD79B mutations in diffuse large b cell lymphoma with bone marrow infiltration: A case report
por: Huang, Wen-Ye, et al.
Publicado: (2022)

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia
por: Lenk, Lennart, et al.
Publicado: (2022)

Peripheral T-Cell Lymphoma with Aberrant Expression of CD19, CD20, and CD79a: Case Report and Literature Review
por: Matnani, Rahul G., et al.
Publicado: (2013)

COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma
por: Gaitzsch, Erik, et al.
Publicado: (2021)

MYD88(L265P) and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy
por: Chen, Rongrong, et al.
Publicado: (2022)

Combinatorics 79
por: Deza, M, et al.
Publicado: (2014)

Combinatorics 79
por: Deza, M, et al.
Publicado: (2014)

Small round tumour cells (CD38, CD 79a positive) in the adrenal gland
por: Nigam, L.A., et al.
Publicado: (2017)

A novel ten-gene prognostic signature for cervical cancer based on CD79B-related immunomodulators
por: Pu, Dan, et al.
Publicado: (2022)

Membrane Proteomics of Arabidopsis Glucosinolate Mutants cyp79B2/B3 and myb28/29
por: Mostafa, Islam, et al.
Publicado: (2017)

EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples
por: Saieg, Mauro Ajaj, et al.
Publicado: (2013)

Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study
por: Herrera, Alex F., et al.
Publicado: (2022)

An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy
por: Rodríguez, Marta, et al.
Publicado: (2022)

CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma
por: Yamaguchi, Junya, et al.
Publicado: (2022)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

Synergistic cooperation and crosstalk between MYD88(L265P) and mutations that dysregulate CD79B and surface IgM
por: Wang, James Q., et al.
Publicado: (2017)

79th Nobel Symposium
por: Gustafsson, B, et al.
Publicado: (1991)

Workshop 79-4
Publicado: (1979)

Workshop 79-01
Publicado: (1979)

Workshop 79-02
Publicado: (1979)

Workshop 79-03
Publicado: (1979)

Conserved Role of unc-79 in Ethanol Responses in Lightweight Mutant Mice
por: Speca, David J., et al.
Publicado: (2010)

Expression of the B-Cell Receptor Component CD79a on Immature Myeloid Cells Contributes to Their Tumor Promoting Effects
por: Luger, Dror, et al.
Publicado: (2013)

CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia
por: Lenk, Lennart, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lhsmeqktt0kq0d6cu5037gug7s